IP Library Granted Patent US 10,029,013
Granted Patent B2
US 10,029,013 · App. 13/499,709 · Granted Jul 24, 2018

Surfactant-free, water-free formable composition and breakable foams and their uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,029,013
App. No.
13/499,709
Granted
Jul 24, 2018
Kind
B2
Abstract

A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or More other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.

Claims (77)

1. A waterless foamable composition free of surfactant and polymeric agent comprising:

a carrier comprising:

a) about 50% to about 90% by weight of the carrier of a liquid oil and about 10% to about 50% by weight of the carrier of a paraffin wax that has a melting point between about 47° C. and about 64° C., wherein the total weight of the liquid oil and paraffin wax together is between about 85% and about 100% by weight of the carrier; or

b) about 40% by weight of the carrier of a liquid oil and about 60% by weight of the carrier of a paraffin wax that has a melting point between about 42° C. and about 44° C.; and

a liquefied or compressed gas propellant; and

a tetracycline antibiotic;

wherein the ratio of the carrier to the propellant is from about 100:4 to about 100:25;

wherein the composition comprises less than 5% foam adjuvant; and

wherein upon dispensing the foamable composition from a container, the composition forms a breakable foam that is stable, yet breaks easily upon application of shear force.

2. The composition of claim 1 , further comprising at least one active agent.

3. The composition of claim 2 , wherein the active agent is selected from the group consisting of an active herbal extract, an acaricide, an age spot and keratose removing agent, an allergen, an alpha hydroxyl acid, an analgesic agent, an antiacne agent, an antiallergic agent, an antiaging agent, an antibacterial agent, an antibiotic, an antiburn agent, an anticancer agent, an antidandruff agent, an antidepressant, an antidermatitis agent, an antiedemic agent, an antifungal agent, an antihistamine, an antihelminth agent, an antihyperkeratolyte agent, an anti-infective agent, an antiinflammatory agent, an antiirritant, an antilipemic agent, an antimicrobial agent, an antimycotic agent, an antioxidant, an antiparasitic agent, an antiproliferative agent, an antipruritic agent, an antipsoriatic agent, an antirosacea agent, an antiseborrheic agent, an antiseptic agent, an antiswelling agent, an antiviral agent, an anti-wart agent, an anti-wrinkle agent, an antiyeast agent, an astringent, a beta-hydroxy acid, benzoyl peroxide, a topical cardiovascular agent, a chemotherapeutic agent, a corticosteroid, an immunogenic substance, a dicarboxylic acid, a disinfectant, a fungicide, a hair growth regulator, a haptene, a hormone, a hydroxy acid, an immunosuppressant, an immunoregulating agent, an immunomodulator, an insecticide, an insect repellent, a keratolytic agent, a lactam, a local anesthetic agent, a lubricating agent, a masking agent, a metals, a metal oxide, a mitocide, a neuropeptide, a non-steroidal anti-inflammatory agent, an oxidizing agent, a pediculicide, a peptide, a protein, a photodynamic therapy agent, a radical scavenger, a refatting agent, a retinoid, a sanative, a scabicide, a self tanning agent, a skin protective agent, a skin whitening agent, a steroid, a steroid hormone, a vasoconstrictor, a vasodilator, a vitamin, a vitamin A, a vitamin A derivative, a vitamin B, a vitamin B derivative, a vitamin C, a vitamin C derivative, a vitamin D, a vitamin D derivative, a vitamin D analog, a vitamin F, a vitamin F derivative, a vitamin K, a vitamin K derivative, a wound healing agent and a wart remover, an androgen, an anti-hyperkeratosis agent, an estrogen, an immunestimulant, a pesticide, a progesterone, a sedative, a vaso active agent, and a mixture of any two or more thereof.

4. The composition of claim 1 , wherein the tetracycline antibiotic is a minocycline or a doxycycline.

5. The composition of claim 3 , wherein the active agent is a retinoid.

6. The composition of claim 1 , wherein the carrier comprises about 1% or less than 1% by weight of a foam adjuvant.

7. The composition of claim 1 , wherein the composition is foam adjuvant free.

8. The composition of claim 1 , wherein the carrier comprises about 5% or less than 5% by weight of the carrier of polyols.

9. The composition of claim 1 , wherein the paraffin wax is selected from the group consisting of a paraffin wax 58-62° C., a paraffin wax 51-53° C., and a paraffin wax 42-44° C., and a mixture thereof.

10. The composition of claim 1 , wherein the composition is free of short chain alcohols.

11. The composition of claim 1 , wherein the composition is a single phase.

12. The composition of claim 1 , further comprising a solid or semi-solid oil.

13. The composition of claim 1 , wherein the composition is short chain alcohol free and polyol free.

14. The composition of claim 1 , wherein the propellant is a hydrocarbon propellant or a hydrofluorocarbon or another environmentally acceptable propellant.

15. The composition of claim 1 , wherein the composition further comprises a wax selected from a hydrogenated castor oil, beeswax, and a mixture thereof.

16. The composition of claim 2 , wherein the active agent is suitable for treating a disorder selected form the group consisting of abscess, acne, acne conglobata, acne fulminans, acne vulgaris, acne scars, acute febrile neutrophilic dermatosis, acute lymphangitis, allergic contact dermatitis, alopecia, athlete's foot, atopic dermatitis, bacterial skin infections, baldness, basal cell carcinoma, blisters, bromhidrosis, bullous pemphigoid, burn, calluses candidiasis, carbuncles, cellulitis, chemical burns, chicken pox, cholesteatoma, cholinergic urticaria, chronic effects of sunlight, cold sores, cold urticaria, comedones, corns, creeping eruption, cutaneous abscess, cutaneous larva migrans, cutaneous myiasis, dark spots, delusional parasitosis, Dercum disease, dermatitis, dermatitis herpetiformis, dermatological pain, dermatological inflammation, dermographism, dermatophytoses, drug eruptions and reactions, dyshidrotic eczema, ectodermal dysplasia, eczema, ecthyma, epidermoid cyst, epidermal necrolysis, erysipelas, erysipelas, erythrasma, exfoliative dermatitis, erythema multiforme, erythema nodosum, folliculitis, fungal nail infections, fungal skin infections, furuncles, gangrene, genital herpes, granuloma annulare, head lice, hidradenitis suppurativa, hives, folliculitis, hirsutism, hyperhidrosis, hypohidrosis, ichthyosis, impetigo, inflammatory acne, ingrown nails, intertrigo, irritant contact dermatitis, ischemic necrosis, itching, jock itch, Kaposi's sarcoma, keratosis pilaris, lichen simplex chronicus, lichen planus, lichen sclerosus, lymphadenitis, lymphadenitis, lymphangitis, malignant melanoma, mastocytosis, measles, melanoma, miliaria, moles, molluscum contagiosum, MRSA, necrotizing subcutaneous infection, necrotizing fasciitis, necrotizing myositis, nodular papulopustular acne, non-inflammatory acne, nummular dermatitis, oral herpes, panniculitis, parapsoriasis paronychia, parasitic skin infections, pemphigus, photo-allergy, photo-damage, photo-irritation, photosensitivity, papules, pediculosis, perioral dermatitis, pimples, pityriasis rosea, pityriasis Lichenoides, pityriasis rosea, pityriasis rubra pilaris, poison ivy, poison oak post-operative or post-surgical skin conditions, pressure ulcers, pressure urticaria, pruritis, pseudofolliculitis barbae, psoriasis, PUPPP, purpura, pustules, pyogenic granuloma, rash, ringworm, rosacea, roseola, rubella, scabies, scalded skin syndrome, scarring, scleroderma, sebaceous cyst, seborrheic dermatitis, seborrheic keratosis, shingles, skin aging, skin cancer, skin neoplasia, skin neoplasms, skin rash, skin ulcers, squamous cell carcinoma, staphylococcal scalded skin syndrome, stasis dermatitis, Stevens-Johnson syndrome, sunburn, sun spots, thermal burns, tinea corporis, tinea cruris, tinea pedis, tinea versicolor, toxic epidermal necrolysis, trauma or injury to the skin, varicella zoster virus, vitamin D deficiency, viral skin infections, vitiligo, warts, water hives, wrinkles, xerosis, yeast skin infections, and zoster.

17. The composition of claim 1 , wherein the composition comprises less than 1% foam adjuvant.

18. The composition of claim 1 , wherein the composition is free of foam adjuvants having a gel building role.

19. A waterless foamable composition free of surfactant and polymeric agent comprising:

a carrier comprising:

a) about 50% to about 90% by weight of the carrier of a liquid oil and about 10% to about 50% by weight of the carrier of a paraffin wax selected from the group consisting of a paraffin wax 58-62° C., a paraffin wax 51-53° C., and a mixture thereof, wherein the total weight of the liquid oil and wax together is between about 85% and about 100% by weight of the carrier; or

b) about 40% by weight of the carrier of a liquid oil and about 60% by weight of the carrier of a paraffin wax 42-44° C.; and

a liquefied or compressed gas propellant, wherein the gas propellant has a vapor pressure of about 40 to about 90 psi;

wherein the ratio of the carrier to the propellant is from about 100:4 to about 100:25;

wherein the composition comprises less than 5% foam adjuvant;

wherein the foamable composition is flowable; and

wherein upon dispensing the foamable composition from a container, the composition forms a breakable foam that is stable, yet breaks easily upon application of shear force.

20. The composition of claim 19 , wherein the composition further comprises a tetracycline antibiotic.

21. The composition of claim 19 , wherein the foamable composition comprises about 5% to about 16% by weight of the gas propellant.

22. The composition of claim 19 , wherein the foamable composition comprises about 7% to about 17% of the gas propellant.

23. The composition of claim 19 , wherein the foamable composition comprises less than about 0.1% by weight polymeric agent.

24. A waterless foamable composition free of surfactant and polymeric agent comprising:

a carrier comprising:

a) about 60% to about 85% by weight of the carrier of a liquid oil and about 15% to about 40% by weight of the carrier of a paraffin wax 58-62° C., a paraffin wax 51-53° C., and a mixture thereof, wherein the total weight of the liquid oil and wax together is between about 85% and about 100% by weight of the carrier; or

b) about 40% by weight of the carrier of a liquid oil and about 60% by weight of the carrier of a paraffin wax 42-44° C.; and

a liquefied or compressed gas propellant;

wherein the ratio of the carrier to the propellant is from about 100:4 to about 100:25;

wherein the composition comprises less than 5% foam adjuvant; and

wherein upon dispensing the foamable composition from a container, the composition forms a breakable foam that is stable, yet breaks easily upon application of shear force.

25. The composition of claim 2 , wherein the active agent is a cosmetic agent.

26. The composition of claim 1 , wherein the liquid oil is selected from a mineral oil, capric/caprylic triglyceride, PPG-15 stearyl ether, isopropyl palmitate, isopropyl myristate, octyldodecanol, and a mixture of two or more thereof.

27. The composition of claim 26 , wherein the liquid oil comprises a mineral oil.

28. The composition of claim 27 , wherein the mineral oil is a heavy mineral oil, a light mineral oil, or a mixture thereof.

29. The composition of claim 19 , wherein the liquid oil is selected from a mineral oil, capric/caprylic triglyceride, PPG-15 stearyl ether, isopropyl palmitate, isopropyl myristate, octyldodecanol, and a mixture of two or more thereof.

30. The composition of claim 29 , wherein the liquid oil comprises a mineral oil.

31. The composition of claim 24 , wherein the liquid oil is selected from a mineral oil, capric/caprylic triglyceride, PPG-15 stearyl ether, isopropyl palmitate, isopropyl myristate, octyldodecanol, and a mixture of two or more thereof.

32. The composition of claim 31 , wherein the liquid oil comprises a mineral oil.

33. The composition of claim 1 , wherein the ratio of the carrier to the propellant is from about 100:8 to about 100:12.

34. The composition of claim 19 , wherein the ratio of the carrier to the propellant is from about 100:8 to about 100:12.

35. The composition of claim 24 , wherein the ratio of the carrier to the propellant is from about 100:8 to about 100:12.

36. A waterless foamable composition free of surfactant and polymeric agent comprising:

a carrier comprising:

a) about 50% to about 90% by weight of the carrier of a liquid oil and about 10% to about 50% by weight of the carrier of a paraffin wax that has a melting point between about 47° C. and about 64° C., wherein the total weight of the liquid oil and paraffin wax together is between about 85% and about 100% by weight of the carrier; or

b) about 40% by weight of the carrier of a liquid oil and about 60% by weight of the carrier of a paraffin wax that has a melting point between about 42° C. and about 44° C.; and

c) an active agent;

wherein the composition comprises less than 5% foam adjuvant; and

wherein, when a liquefied propellant is added to the foamable composition in an aerosol in an amount effective to achieve an acceptable foam, the composition forms a breakable foam upon dispensing that is stable, yet breaks easily upon application of shear force.

37. The composition of claim 36 , wherein the ratio of the carrier to the propellant is from about 100:4 to about 100:25.

38. The composition of claim 36 , wherein the ratio of the carrier to the propellant is from about 100:8 to about 100:12.

39. The composition of claim 36 , wherein the liquid oil is selected from a mineral oil, capric/caprylic triglyceride, PPG-15 stearyl ether, isopropyl palmitate, isopropyl myristate, octyldodecanol, and a mixture of two or more thereof.

40. The composition of claim 39 , wherein the liquid oil comprises a mineral oil.

41. The composition of claim 40 , wherein the mineral oil is a heavy mineral oil, a light mineral oil, or a mixture thereof.

42. The composition of claim 36 , wherein the paraffin wax is selected from a paraffin wax 58-62° C., a paraffin wax 51-53° C., and a mixture thereof.

43. The composition of claim 1 , wherein the liquid oil comprises a mineral oil, a soybean oil, a coconut oil, a silicone oil or a mixture of any two or more thereof.

44. The composition of claim 19 , wherein the liquid oil comprises a mineral oil, a soybean oil, a coconut oil, a silicone oil or a mixture of any two or more thereof.

45. The composition of claim 24 , wherein the liquid oil comprises a mineral oil, a soybean oil, a coconut oil, a silicone oil or a mixture of any two or more thereof.

46. The composition of claim 36 , wherein the liquid oil comprises a mineral oil, a soybean oil, a coconut oil, a silicone oil or a mixture of any two or more thereof.

47. The composition of claim 36 , wherein the active agent comprises a doxycycline, a minocycline, or both.

48. The composition of claim 36 , wherein the active agent comprises a tetracycline.

Assignments (11)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0167 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
CHANGE OF NAME Recorded Jul 30, 2014
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS LTD.
Reel/Frame 033445/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2012
From: TAMARKIN, DOV; GAZAL, ELANA; PAPIASHVILI, IRAKLIY; HAZOT, YOHAN; SCHUZ, DAVID; KEYNAN, RITA
To: FOAMIX LTD.
Reel/Frame 028938/0176 →